JP2019504029A - クラスｉｉａ ｈｄａｃ阻害剤の使用方法 - Google Patents

クラスｉｉａ ｈｄａｃ阻害剤の使用方法 Download PDF

Info

Publication number
JP2019504029A
JP2019504029A JP2018532723A JP2018532723A JP2019504029A JP 2019504029 A JP2019504029 A JP 2019504029A JP 2018532723 A JP2018532723 A JP 2018532723A JP 2018532723 A JP2018532723 A JP 2018532723A JP 2019504029 A JP2019504029 A JP 2019504029A
Authority
JP
Japan
Prior art keywords
tumor
subject
cancer
cell
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018532723A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019504029A5 (https=
Inventor
ショミール、ゴーシュ
ジェニファー、ゲリエロ
ラウレンス、クラウデニアー
アンソニー、レタイ
メルセデス、ロベラ
パルウィンダー、ケイ．マンダー
マイケル、アレクサンダー、ノーラン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline LLC
Original Assignee
GlaxoSmithKline LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline LLC filed Critical GlaxoSmithKline LLC
Publication of JP2019504029A publication Critical patent/JP2019504029A/ja
Publication of JP2019504029A5 publication Critical patent/JP2019504029A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2018532723A 2015-12-22 2016-12-22 クラスｉｉａ ｈｄａｃ阻害剤の使用方法 Pending JP2019504029A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562270835P 2015-12-22 2015-12-22
US62/270,835 2015-12-22
US201662350224P 2016-06-15 2016-06-15
US62/350,224 2016-06-15
US201662399149P 2016-09-23 2016-09-23
US62/399,149 2016-09-23
PCT/US2016/068184 WO2017112838A1 (en) 2015-12-22 2016-12-22 METHODS OF USE OF A CLASS llA HDAC INHIBITOR

Publications (2)

Publication Number Publication Date
JP2019504029A true JP2019504029A (ja) 2019-02-14
JP2019504029A5 JP2019504029A5 (https=) 2020-02-06

Family

ID=59091176

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018532723A Pending JP2019504029A (ja) 2015-12-22 2016-12-22 クラスｉｉａ ｈｄａｃ阻害剤の使用方法

Country Status (4)

Country Link
US (1) US20200268720A1 (https=)
EP (1) EP3393458A4 (https=)
JP (1) JP2019504029A (https=)
WO (1) WO2017112838A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023008459A1 (ja) * 2021-07-27 2023-02-02 東レ株式会社 癌の治療及び／又は予防のための医薬品

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
KR102237527B1 (ko) * 2017-08-31 2021-04-07 차의과학대학교 산학협력단 성숙 수지상 세포 검출용 바이오마커 및 이의 용도
WO2020202005A1 (en) * 2019-04-02 2020-10-08 Inxmed (Shanghai) Co., Ltd. Combination of a fak kinase inhibitor and an agent targeting t-cell co-stimulatory receptors
CN115778950B (zh) * 2022-11-23 2024-01-26 山西医科大学第二医院 组蛋白去乙酰化酶抑制剂tmp195在制备促进成骨形成药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849589A (en) * 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
JP2009514891A (ja) * 2005-11-04 2009-04-09 メルク エンド カムパニー インコーポレーテッド 癌を治療するためのｓａｈａ及びエルロチニブを用いる方法
WO2010115115A1 (en) * 2009-04-03 2010-10-07 Inserm ( Institut National De La Sante Et De La Recherche) Dendritic cell-boosted humanized immune system mice
WO2012018499A2 (en) * 2010-08-05 2012-02-09 Acetylon Pharmaceuticals Specific regulation of cytokine levels by hdac6 inhibitors
WO2012106343A2 (en) * 2011-02-01 2012-08-09 The Board Of Trustees Of The University Of Illinois Hdac inhibitors and therapeutic methods using the same

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CANCER RES., (2012), 73, [4], P.1386-1399, JPN6020044926, ISSN: 0004529305 *
J. MED. CHEM., (2013), 56, [2], P.427-436, JPN6020044930, ISSN: 0004529307 *
PROTEIMICS CLIN. APPL., (2014), 8, [11-12], P.924-931, JPN6020044928, ISSN: 0004529306 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023008459A1 (ja) * 2021-07-27 2023-02-02 東レ株式会社 癌の治療及び／又は予防のための医薬品

Also Published As

Publication number Publication date
EP3393458A1 (en) 2018-10-31
EP3393458A4 (en) 2019-08-14
WO2017112838A1 (en) 2017-06-29
US20200268720A1 (en) 2020-08-27

Similar Documents

Publication Publication Date Title
US12466888B2 (en) Methods of treating tumor
JP6884185B2 (ja) 骨髄由来抑制細胞の抑制及び免疫チェックポイント阻害の方法
Xiao et al. DKK2 imparts tumor immunity evasion through β-catenin-independent suppression of cytotoxic immune-cell activation
US20240190963A1 (en) Methods of treating tumor
JP2019504029A (ja) クラスｉｉａ ｈｄａｃ阻害剤の使用方法
Burger et al. B cell receptor signaling in chronic lymphocytic leukemia
Gu et al. Notch signaling: its roles and therapeutic potential in hematological malignancies
AU2018359967A1 (en) Diagnostic and therapeutic methods for cancer
US12479917B2 (en) Methods of treating NSCLC comprising administering platinum doublet chemotherapy followed by an anti-PD-1 antibody and an anti-CTLA-4 antibody
JP2020164539A (ja) 腫瘍免疫寛容を破綻させるためのｙａｐの阻害方法
López-Guerra et al. Specific NOTCH1 antibody targets DLL4-induced proliferation, migration, and angiogenesis in NOTCH1-mutated CLL cells
TWI656875B (zh) 藉二氫吡并吡治療癌症
JP2019512271A (ja) Ｔ細胞疲弊状態特異的遺伝子発現調節因子およびその使用
CN111148518A (zh) 使用cdk4/6抑制剂调控调节性t细胞和免疫应答的方法
Eglenen-Polat et al. A telomere-targeting drug depletes cancer initiating cells and promotes anti-tumor immunity in small cell lung cancer
Matas-Céspedes et al. Disruption of follicular dendritic cells–follicular lymphoma cross-talk by the Pan-PI3K inhibitor BKM120 (Buparlisib)
JP2023546217A (ja) がん、自己免疫障害、及び炎症性障害の処置におけるｎ－ミリストイルトランスフェラーゼ（ｎｍｔ）阻害剤の使用
JP2025011250A (ja) 免疫応答を調節するためのＩＲＥ１α－ＸＢＰ１シグナル伝達経路バイオマーカーの使用
JP2014529359A (ja) 投与および治療の方法
TW201838655A (zh) 抑制低密度脂蛋白受體相關蛋白５以抑制腫瘤形成
De Leon et al. An ultrasmall core–shell silica nanoparticle improves antitumour immunity and survival by remodelling suppressive melanoma microenvironments
CN115698717A (zh) 癌症的治疗和诊断方法
Mousavi et al. Tumor microenvironment as a novel therapeutic target for lymphoid leukemias
Lin et al. CXCL10-induced regulatory T cells and adenosine signaling promote immunosuppression and progression of epithelial ovarian cancer
Jasim et al. A comprehensive review of immunotherapy in gastrointestinal tumors with a focus on the role of combination therapy with PARP inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191218

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201124

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210618